Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.
According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.
The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.